IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 99.43

Change

+0.41 (+0.41)%

Market Cap

N/A

Volume

0.09M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.56 (+0.36%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

+0.29 (+0.39%)

USD 3.02B
FXH First Trust Health Care AlphaD..

+0.84 (+0.75%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+1.18 (+1.31%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.23 (+0.94%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.98 (+2.59%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.11 (-0.11%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.35 (+1.18%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.87 (+1.35%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.77 (+2.70%)

USD 0.01B

ETFs Containing IXJ

XHC:CA iShares Global Healthcare.. 99.91 % 0.65 %

+0.19 (+-0.42%)

CAD 0.65B
IXJ:AU iShares Global Healthcare.. 99.88 % 0.00 %

-0.61 (-0.42%)

USD 1.47B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.66% 71% C- 70% C-
Dividend Return 0.78% 80% B- 18% F
Total Return 15.43% 76% C+ 66% D+
Trailing 12 Months  
Capital Gain 19.36% 43% F 60% D-
Dividend Return 1.47% 94% A 22% F
Total Return 20.84% 43% F 55% F
Trailing 5 Years  
Capital Gain 60.29% 71% C- 75% C
Dividend Return 6.18% 72% C 19% F
Total Return 66.48% 71% C- 73% C
Average Annual (5 Year Horizon)  
Capital Gain 7.46% 67% D+ 63% D
Dividend Return 8.42% 67% D+ 58% F
Total Return 0.96% 74% C 21% F
Risk Return Profile  
Volatility (Standard Deviation) 10.68% 95% A 76% C+
Risk Adjusted Return 78.76% 81% B- 90% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike